| AVOREN: Bevacizumab plus interferon extended OS in metastatic renal cell carcinoma - HemOncToday |
|
|
HemOncToday... showed that the combination of bevacizumab and interferon alfa-2a improved OS as first-line therapy in patients with metastatic renal cell carcinoma. ... read more |